Privo Technologies, founded in 2010 and based in Cambridge, United States, specializes in the manufacturing and processing of pharmaceutical preparations for both human and veterinary use. The company's core mission is to develop innovative therapeutics that eliminate cancers and prevent their recurrence, while making treatments more accessible and easier on patients. Privo Technologies offers a range of products under its PRV™ system, including PRV 111, PRV 131, and PRV 211, focusing on clinical trials and expanded access to cutting-edge cancer treatments.

Notable affiliated individuals include experts in pharmaceutical sciences and oncology, contributing to the company's robust research and development efforts. Privo Technologies has garnered attention from significant investors in the biotech sector, aiding in its growth and innovation. Key achievements include advancements in their PRV™ system and successful clinical trials, which have positioned the company as a promising player in the fight against cancer. Their impact is reflected in their commitment to providing hope through more effective and patient-friendly cancer treatments.